• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

PPI 诱导的血浆代谢物水平变化对英国队列的全髋关节骨密度有影响。

PPI-Induced Changes in Plasma Metabolite Levels Influence Total Hip Bone Mineral Density in a UK Cohort.

机构信息

Department of Twins Research & Genetics Epidemiology, King's College London, London, UK.

出版信息

J Bone Miner Res. 2023 Feb;38(2):326-334. doi: 10.1002/jbmr.4754. Epub 2022 Dec 30.

DOI:10.1002/jbmr.4754
PMID:36458982
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10108201/
Abstract

Proton pump inhibitors (PPIs) are among the most used drugs in the UK. PPI use has been associated with decreased bone mineral density (BMD) and increased fracture risk, although these results have been inconsistent. We hypothesized that PPI could modulate BMD by altering gut and/or host systemic metabolic environments. Using data from more than 5000 British male and female individuals, we confirmed that PPI use is associated with decreased lumbar spine and total hip BMD. This effect was not mediated through the gut microbiome. We suggest here that PPI use may influence total hip BMD, both directly and indirectly, via plasma metabolites involved in the sex hormone pathway. © 2022 The Authors. Journal of Bone and Mineral Research published by Wiley Periodicals LLC on behalf of American Society for Bone and Mineral Research (ASBMR).

摘要

质子泵抑制剂 (PPIs) 是英国使用最广泛的药物之一。尽管这些结果并不一致，但 PPI 的使用与骨密度 (BMD) 降低和骨折风险增加有关。我们假设 PPI 可以通过改变肠道和/或宿主系统代谢环境来调节 BMD。我们使用来自 5000 多名英国男性和女性的数据证实，PPI 的使用与腰椎和全髋关节 BMD 降低有关。这种影响不是通过肠道微生物组介导的。我们在这里提出，PPI 的使用可能会通过参与性激素途径的血浆代谢物直接和间接地影响全髋关节 BMD。© 2022 作者。由 Wiley Periodicals LLC 代表美国骨骼和矿物质研究协会 (ASBMR) 出版的《骨与矿物研究杂志》。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/483d/10108201/007dd72dc9bb/JBMR-38-326-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/483d/10108201/3747ac4228fd/JBMR-38-326-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/483d/10108201/007dd72dc9bb/JBMR-38-326-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/483d/10108201/3747ac4228fd/JBMR-38-326-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/483d/10108201/007dd72dc9bb/JBMR-38-326-g002.jpg

相似文献

1
PPI-Induced Changes in Plasma Metabolite Levels Influence Total Hip Bone Mineral Density in a UK Cohort.PPI 诱导的血浆代谢物水平变化对英国队列的全髋关节骨密度有影响。
J Bone Miner Res. 2023 Feb;38(2):326-334. doi: 10.1002/jbmr.4754. Epub 2022 Dec 30.
2
Proton-pump inhibitor use is not associated with osteoporosis or accelerated bone mineral density loss.质子泵抑制剂的使用与骨质疏松或骨密度加速丢失无关。
Gastroenterology. 2010 Mar;138(3):896-904. doi: 10.1053/j.gastro.2009.11.014. Epub 2009 Nov 18.
3
The relationship between proton pump inhibitor use and longitudinal change in bone mineral density: a population-based study [corrected] from the Canadian Multicentre Osteoporosis Study (CaMos).质子泵抑制剂使用与骨密度纵向变化的关系：来自加拿大多中心骨质疏松研究（CaMos）的一项基于人群的研究[更正]。
Am J Gastroenterol. 2012 Sep;107(9):1361-9. doi: 10.1038/ajg.2012.200. Epub 2012 Jul 10.
4
Esomeprazole use is independently associated with significant reduction of BMD: 1-year prospective comparative safety study of four proton pump inhibitors.埃索美拉唑的使用与骨密度显著降低独立相关：四种质子泵抑制剂的1年前瞻性比较安全性研究。
J Bone Miner Metab. 2016 Sep;34(5):571-9. doi: 10.1007/s00774-015-0699-6. Epub 2015 Jul 25.
5
Fracture risk and bone mineral density reduction associated with proton pump inhibitors.质子泵抑制剂相关的骨折风险和骨密度降低。
Pharmacotherapy. 2012 Jan;32(1):67-79. doi: 10.1002/PHAR.1007.
6
Bone mineral density changes among women initiating proton pump inhibitors or H2 receptor antagonists: a SWAN cohort study.开始使用质子泵抑制剂或H2受体拮抗剂的女性的骨矿物质密度变化：一项SWAN队列研究。
J Bone Miner Res. 2015 Feb;30(2):232-9. doi: 10.1002/jbmr.2344.
7
Sex-specific Association of Chronic Proton Pump Inhibitor Use With Reduced Bone Density and Quality.长期使用质子泵抑制剂与骨密度和质量降低之间的性别特异性关联。
J Clin Endocrinol Metab. 2025 May 19;110(6):e2071-e2079. doi: 10.1210/clinem/dgae598.
8
Proton pump inhibitors use and change in bone mineral density.质子泵抑制剂的使用与骨矿物质密度的变化
Int J Rheum Dis. 2016 Sep;19(9):864-8. doi: 10.1111/1756-185X.12866. Epub 2016 May 31.
9
Correlation of Bone Mineral Density Scores and Proton Pump Inhibitors Use in the Elderly.老年人骨密度评分与质子泵抑制剂使用情况的相关性
Curr Rheumatol Rev. 2016;12(2):162-6. doi: 10.2174/1573397111666151026222921.
10
Proton pump inhibitor use, hip fracture, and change in bone mineral density in postmenopausal women: results from the Women's Health Initiative.绝经后女性使用质子泵抑制剂、髋部骨折与骨矿物质密度变化：妇女健康倡议的结果
Arch Intern Med. 2010 May 10;170(9):765-71. doi: 10.1001/archinternmed.2010.94.

引用本文的文献

1
Adipose tissue gene expression and longitudinal clinical phenotypes are early biomarkers of lipid-regulating drug usage.脂肪组织基因表达和纵向临床表型是脂质调节药物使用的早期生物标志物。
Sci Rep. 2025 Aug 29;15(1):31861. doi: 10.1038/s41598-025-13693-x.
2
Longitudinal association of perfluorooctanoic acid (PFOA) and perfluorooctanesulfonic acid (PFOS) exposure with lipid traits, in a healthy unselected population.在一个未经过筛选的健康人群中，全氟辛酸（PFOA）和全氟辛烷磺酸（PFOS）暴露与血脂特征的纵向关联。
J Expo Sci Environ Epidemiol. 2025 Apr 24. doi: 10.1038/s41370-025-00773-3.
3
Multifluid Metabolomics Identifies Novel Biomarkers for Irritable Bowel Syndrome.

本文引用的文献

1
An online atlas of human plasma metabolite signatures of gut microbiome composition.肠道微生物组成的人类血浆代谢物特征的在线图谱。
Nat Commun. 2022 Sep 23;13(1):5370. doi: 10.1038/s41467-022-33050-0.
2
Lansoprazole-induced osteoporosis via the IP3R- and SOCE-mediated calcium signaling pathways.兰索拉唑通过 IP3R 和 SOCE 介导的钙信号通路诱导骨质疏松症。
Mol Med. 2022 Feb 19;28(1):21. doi: 10.1186/s10020-022-00448-x.
3
Endogenous DHEAS Is Causally Linked With Lumbar Spine Bone Mineral Density and Forearm Fractures in Women.内源性脱氢表雄酮与女性腰椎骨密度和前臂骨折有因果关系。
多流体代谢组学鉴定肠易激综合征的新型生物标志物。
Metabolites. 2025 Feb 12;15(2):121. doi: 10.3390/metabo15020121.
4
Sex-specific Association of Chronic Proton Pump Inhibitor Use With Reduced Bone Density and Quality.长期使用质子泵抑制剂与骨密度和质量降低之间的性别特异性关联。
J Clin Endocrinol Metab. 2025 May 19;110(6):e2071-e2079. doi: 10.1210/clinem/dgae598.
5
Continuous co-prescription of rebamipide prevents upper gastrointestinal bleeding in NSAID use for orthopaedic conditions: A nested case-control study using the LIFE Study database.连续共开瑞巴派特可预防骨科疾病 NSAID 使用相关上消化道出血：使用 LIFE 研究数据库的巢式病例对照研究。
PLoS One. 2024 Jun 11;19(6):e0305320. doi: 10.1371/journal.pone.0305320. eCollection 2024.
J Clin Endocrinol Metab. 2022 Apr 19;107(5):e2080-e2086. doi: 10.1210/clinem/dgab915.
4
Effect of Omeprazole on Osteoblasts and Osteoclasts in vivo and in the in vitro Model Using Fish Scales.鱼鳞片体外和体内模型中奥美拉唑对成骨细胞和破骨细胞的影响。
Biochemistry (Mosc). 2021 Oct;86(10):1192-1200. doi: 10.1134/S0006297921100035.
5
Serum metabolomic analysis reveals several novel metabolites in association with excessive alcohol use - an exploratory study.血清代谢组学分析揭示了与过量饮酒相关的几种新型代谢物 - 一项探索性研究。
Transl Res. 2022 Feb;240:87-98. doi: 10.1016/j.trsl.2021.10.008. Epub 2021 Nov 3.
6
A Distinctive Human Metabolomics Alteration Associated with Osteopenic and Osteoporotic Patients.与骨质减少和骨质疏松患者相关的独特人类代谢组学改变
Metabolites. 2021 Sep 16;11(9):628. doi: 10.3390/metabo11090628.
7
Integrating taxonomic, functional, and strain-level profiling of diverse microbial communities with bioBakery 3.利用 bioBakery 3 整合具有分类学、功能和菌株水平特征的多样化微生物群落。
Elife. 2021 May 4;10:e65088. doi: 10.7554/eLife.65088.
8
The Gut Microbiome Is Altered in Postmenopausal Women With Osteoporosis and Osteopenia.骨质疏松症和骨质减少的绝经后女性肠道微生物群发生改变。
JBMR Plus. 2021 Jan 19;5(3):e10452. doi: 10.1002/jbm4.10452. eCollection 2021 Mar.
9
Dietary Taxifolin Protects Against Dextran Sulfate Sodium-Induced Colitis NF-κB Signaling, Enhancing Intestinal Barrier and Modulating Gut Microbiota.膳食圣草次苷防治葡聚糖硫酸钠诱导的结肠炎：NF-κB 信号通路、增强肠道屏障和调节肠道微生物群。
Front Immunol. 2021 Feb 16;11:631809. doi: 10.3389/fimmu.2020.631809. eCollection 2020.
10
Metabolomics Insights into Osteoporosis Through Association With Bone Mineral Density.通过与骨密度的关联对骨质疏松症进行代谢组学研究。
J Bone Miner Res. 2021 Apr;36(4):729-738. doi: 10.1002/jbmr.4240. Epub 2021 Feb 2.